ESMO 2018 | Immunotherapy for lung cancer: current landscape and challenges

Keith Kerr

Developments in lung cancer are ever-increasing, with a multitude of novel immuno-oncology agents becoming available. Here, Keith Kerr, MBChB, FRCPath, FRCPE, of Aberdeen University Medical School, Aberdeen, UK, discusses the current immunotherapeutic landscape for lung cancer. This video was recorded at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.

Share this video